Blood Test
To Detect
Cancer
Screen for Early Indicators
of Cancer with HrC Genomics
Blood Test to Detect Cancer
Unlocking Insights with Next Generation Sequencing (NGS)
HrC Genomics leverages the power of Next Generation Sequencing (NGS) to analyse blood samples, providing valuable insights into potential cancer risk. NGS is a cutting-edge technology that meticulously examines RNA and DNA, revealing genetic variations associated with diseases, specifically cancer in this context.
Our process utilises two distinct yet complementary NGS techniques:
- Whole Exome Sequencing: This method focuses on the protein-coding regions of DNA (the exome). Analysis of these regions identifies gene mutations that may contribute to certain diseases. Mutations can lead to the production of faulty proteins, disrupting crucial bodily functions.
- Whole Transcriptome Sequencing: This technique also targets the protein-coding regions but analyses RNA instead of DNA. RNA provides a snapshot of gene expression, indicating which genes are active or inactive. Variations in RNA expression (either up or down regulation) can be linked to specific diseases such as cancer.
Combining these two approaches allows us to detect DNA mutations and associated changes in gene expression. This dual analysis provides a more comprehensive view, aiding in biomarker detection and offering a clearer picture of potential cancer risk.
HrC Technology: Interpreting the Data
The raw data generated from NGS analysis is processed using our proprietary HrC technology. Developed by a team of scientists at Epigeneres Biotech in Mumbai, this technology is based on the innovative concept of Very Small Embryonic-Like Stem Cells (VSELs).
The hypothesis suggests that these VSELs residing in tissue can undergo epigenetic changes and transform into Cancer Stem Cells. As this transformation occurs, these Cancer Stem Cells are released into the bloodstream in increased numbers. The degree of this increase directly correlates with an individual’s potential cancer risk.
The HrC Score: Your Personalised Risk Indicator
The outcome of this sophisticated analysis is the HrC Score, a metric representing the level of VSEL activity observed in a blood sample. This score is interpreted using the HrC Scale to indicate the risk of cancer presence.
Important Note:
It is important to note that HrC Genomics does not diagnose cancer. It serves as a risk assessment tool, indicating potential cancer presence. Individuals experiencing symptoms suggestive of cancer should seek immediate consultation with their General Practitioner (GP).
Arranging A Test
Ordering Your HrC Genomics Test
Important Precaution:
Please note that this test is not suitable for pregnant individuals.
To order your HrC Genomics test, please follow these simple steps:
- Initiate Your Order: Click the “Order HrC Genomics” button. This will direct you to our secure online ordering page.
- Select Quantity and Add to Basket: Specify the number of individuals requiring the test and add the selection to your shopping basket.
- Secure Checkout and Payment: Proceed to checkout and complete the payment process.
- Confirmation and Next Steps: Upon successful payment, a “Thank You” page will appear, providing detailed instructions.
- Complete the Patient Information & Consent Form: Locate and click the link under “For HrC Genomics & All Organ Biopsy Orders.” Each individual undergoing the test must complete this form.
- Schedule Your Phlebotomy Appointment: After submitting the consent form, you will receive an email containing a link to our booking page. Here, you can schedule your with a qualified phlebotomist at one of our partner clinics in London.
Sample Processing
Samples are processed using Next Generation Sequencing (NGS) Technology.
NGS is a technology that allows the determination of the sequence of DNA and RNA molecules in a fast, accurate and cost-effective way.
For the purposes of HrC, two sequencing methods are utilised, Whole Exome Sequencing and Whole Transcriptome Sequencing.
These two sequencing methods target identified genes that serve as indicators for the presence of cancer.
Sequencing is a complex process which can take up to 3 weeks to generate the raw data required for analysis, interpretation and ultimately to determine the HrC Score for a blood sample.
Data Analysis
The raw data generated through the NGS processing is analysed and interpreted by scientists with in-depth knowledge of the HrC technology.
The only scientists equipped with the relevant knowledge and expertise to perform this function are the scientists at Epigeneres Biotech one of the co-developers of the HrC technology.
The output of the raw data analysis will determine the Hrc Score which, when applied to the HrC Scale, gives a reading that indicates an individual’s risk of cancer presence, i.e., none, negligible, low, medium, or high.
Finally, once the HrC Score has been determined and the information provided on the Patient Information Form has been taken into consideration, a report will be issued containing the HrC Score, the scientist’s analysis of the data and their interpretation of the same.
